"Savara Inc. Announces $75 Million Royalty Funding Agreement with RTW Investments for MOLBREEVI Pending FDA Approval"

"Savara Inc., a biopharmaceutical company specializing in rare respiratory diseases, has entered into a $75 million royalty funding agreement with RTW Investments, contingent on FDA approval of its drug MOLBREEVI for autoimmune PAP treatment. RTW will receive a tiered single-digit percentage of MOLBREEVI's annual U.S. net sales, subject to a cap."

Latham & Watkins LLP represented RTW Investments, LP in the transaction. Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, entered into a US$75 million royalty funding agreement with funds managed by RTW Investments, LP. The agreement is contingent upon FDA approval of MOLBREEVI and satisfaction of certain customary conditions. Under the terms of the agreement, RTW will receive a tiered single-digit percentage of annual net sales of MOLBREEVI in the US for the treatment of autoimmune PAP, subject to a cap. The Latham & Watkins LLP team advising RTW was led by Bay Area partner Todd Trattner, with associates Axel Magnusson and William Lane. Additional advice was provided by Los Angeles partner Eric Cho on tax matters and Orange County partner Drew Capurro on capital markets matters.

"Savara Inc. Announces $75 Million Royalty Funding Agreement with RTW Investments for MOLBREEVI Pending FDA Approval"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads